ARHGAP17 Antibody

What is ARHGAP17 and what cellular functions does it regulate?

ARHGAP17 (also known as RICH1, NADRIN, and several other aliases) is a GTPase-activating protein that accelerates GTP hydrolysis in Ras-related proteins, particularly Cdc42, converting it to an inactive GDP-bound state. This protein contains both BAR and RhoGAP domains, which are critical for its function in regulating membrane dynamics and GTPase activity respectively .

ARHGAP17 plays several key regulatory roles:

• Maintenance of tight junctions in epithelial cells through regulation of Cdc42 activity

• Establishment of apical polarity in epithelial cells

• Regulation of transcellular transport mechanisms

• Maintenance of intestinal barrier integrity

• Negative regulation of invadopodia formation and cancer cell invasion

Importantly, ARHGAP17 serves as a peripheral membrane protein that localizes to both the cytosol and plasma membrane, with particular enrichment at tight junctions .

What expression patterns and tissue distribution should be considered when using ARHGAP17 antibodies?

ARHGAP17 exhibits specific tissue distribution patterns that researchers should consider when designing experiments:

• Nervous system: Expressed in the cerebellum, hippocampus, and cerebral cortex

• Gastrointestinal tract: Expression limited to the luminal epithelium of intestine

• Cardiovascular system: Particularly high expression in heart

• Reproductive system: Strong expression in placenta

• Cellular level: Human Protein Atlas data suggests strong RNA-level expression in oligodendrocytes

When validating antibody specificity, selecting appropriate positive control tissues based on these expression patterns is crucial. Heart and placental tissues represent optimal positive controls due to their high ARHGAP17 expression levels .

How should I select an appropriate ARHGAP17 antibody for my experimental needs?

When selecting an ARHGAP17 antibody, consider these critical factors:

• Epitope location: Antibodies targeting different domains may yield varying results. For example, antibodies recognizing the internal region (amino acids 303-327) have demonstrated good specificity in multiple applications .

• Validation methods: Prioritize antibodies validated through multiple methods, including western blotting with ARHGAP17 knockout controls and immunofluorescence specificity testing.

• Application compatibility: Not all antibodies perform equally across applications. Some ARHGAP17 antibodies are optimized for specific techniques (WB, IF, IHC, IP).

• Host species: Consider host species compatibility with your experimental system to avoid cross-reactivity issues.

• Clone type: Both monoclonal (like G-6) and polyclonal antibodies are available, each with advantages depending on your application .

How can ARHGAP17 antibodies be used to investigate invadopodia dynamics in cancer research?

ARHGAP17 functions as a negative regulator of invadopodia formation in cancer cells, making ARHGAP17 antibodies valuable tools for studying cancer invasion mechanisms. Research has demonstrated that:

• Silencing ARHGAP17 expression results in a significant increase in the percentage of cells forming invadopodia (from ~29% in control cells to ~79% in knockdown cells)

• ARHGAP17 knockout cells exhibit approximately three-fold increased matrix degradation capacity compared to control cells

• ARHGAP17 knockout spheroids demonstrate significantly enhanced invasive properties in 3D models

For optimal experimental design, researchers should:

• Use ARHGAP17 antibodies to confirm its localization at invadopodia clusters, as endogenous ARHGAP17 shows clear signal at these structures in PDBu-treated cells

• Employ super-resolution microscopy (STORM) to precisely define ARHGAP17's spatial organization within invadopodia, revealing its distribution relative to core (F-actin/cortactin) and ring (paxillin) components

• Design time-course experiments to assess invadopodia dynamics, as ARHGAP17-depleted cells show altered invadopodia formation kinetics with higher initial formation rates and defects in disassembly

These approaches can provide mechanistic insights into how ARHGAP17 regulates cancer cell invasion through modulation of invadopodia turnover.

What are the methodological considerations for investigating ARHGAP17's role in intestinal barrier function?

ARHGAP17 plays a critical role in maintaining intestinal barrier integrity, making it an important target for studies on intestinal disorders. When investigating this role:

• In vivo models: Utilize Arhgap17-deficient mice, which exhibit increased paracellular permeability and aberrant localization of the apical junction complex in intestinal epithelium

• Barrier challenge experiments: Subject Arhgap17-deficient mice to barrier stressors like dextran sulfate sodium (DSS), which reveals that ARHGAP17 deficiency leads to increased DSS accumulation in intraluminal cells, enhanced TNF production, and rapid destruction of the inner mucus layer

• Tissue-specific analysis: Focus immunostaining on the luminal epithelium of intestine where ARHGAP17 expression is concentrated

• Double labeling: Combine ARHGAP17 antibodies with tight junction markers to assess colocalization and integrity of the apical junction complex

When designing these experiments, it's important to note that while Arhgap17-deficient mice show barrier abnormalities, they do not develop spontaneous colitis under normal conditions, suggesting compensatory mechanisms that maintain basic barrier function despite ARHGAP17 absence .

How should ARHGAP17 antibodies be used to investigate potential cross-reactivity with other ARHGAP family members?

Due to significant sequence homology between ARHGAP17, ARHGAP26, and ARHGAP10, particularly within the RhoGAP domain, investigating potential cross-reactivity is crucial for accurate data interpretation:

• Domain-specific antibodies: Use antibodies targeting unique regions outside the conserved RhoGAP domain to minimize cross-reactivity

• Validation in knockout systems: Test antibody specificity in cells lacking ARHGAP17, ARHGAP26, or ARHGAP10 to confirm target selectivity

• Competition assays: Perform blocking peptide experiments with specific peptides from each protein to determine antibody specificity

• Correlation analysis: When studying autoimmune conditions, assess whether ARHGAP17-IgG/anti-Ca titers correlate with ARHGAP26-IgG/anti-Ca titers, which would suggest cross-reactivity rather than distinct antibody populations

This approach is particularly important in autoimmune encephalitis research, where reactivity with ARHGAP17 was found by in-silico re-evaluation of experiments that initially identified ARHGAP26 as a target antigen in autoimmune cerebellar ataxia .

What controls are essential when using ARHGAP17 antibodies for immunofluorescence studies?

Rigorous controls are critical for reliable immunofluorescence experiments with ARHGAP17 antibodies:

Essential negative controls:

• ARHGAP17 knockout or knockdown samples to confirm antibody specificity

• Secondary antibody-only controls to assess background fluorescence

• Isotype controls (matched IgG subclass) to identify non-specific binding

Positive controls and validation approaches:

• Cells overexpressing myc-tagged ARHGAP17 or ARHGAP17-GFP to confirm antibody reactivity

• Rescue experiments demonstrating that re-expression of ARHGAP17 in knockout cells restores antibody signal

• Co-localization with known ARHGAP17-interacting partners or structures (e.g., tight junctions)

Specialized controls for specific experimental contexts:

• For invadopodia studies: Compare PDBu-treated versus untreated cells, as PDBu induces invadopodia formation where ARHGAP17 localizes

• For tight junction studies: Use calcium-switch assays to manipulate junction integrity and observe ARHGAP17 redistribution

By implementing these controls, researchers can confidently interpret ARHGAP17 localization patterns and avoid artifacts common in immunofluorescence studies.

How can I optimize ARHGAP17 antibody performance for western blotting applications?

Optimal western blotting with ARHGAP17 antibodies requires careful consideration of several technical factors:

Sample preparation:

• Include protease inhibitors to prevent degradation of ARHGAP17

• Consider phosphatase inhibitors if studying ARHGAP17 phosphorylation status

• Use appropriate lysis buffers that effectively solubilize membrane-associated proteins

Electrophoresis conditions:

• Use gradient gels (4-12%) to efficiently resolve ARHGAP17

• Consider longer running times to achieve clear separation from similarly sized proteins

Transfer and detection optimization:

• Optimize transfer conditions for higher molecular weight proteins

• Test a range of antibody dilutions (typically 1:200-1:1000) to determine optimal signal-to-noise ratio

• Include positive controls (tissues with high ARHGAP17 expression like heart or placenta)

Validation strategies:

• Always include ARHGAP17 knockout or knockdown samples as specificity controls

• The antibody should detect a single band of the expected molecular weight, which disappears in knockout samples

• Consider using multiple antibodies targeting different epitopes to confirm specificity

These optimization steps are essential for generating reliable and reproducible western blot data when studying ARHGAP17.

What are the most common pitfalls when using ARHGAP17 antibodies, and how can they be avoided?

Researchers should be aware of several common challenges when working with ARHGAP17 antibodies:

Cross-reactivity with related proteins:

• Problem: Due to sequence homology with ARHGAP26 and ARHGAP10, antibodies may recognize multiple family members

• Solution: Validate antibody specificity using knockout controls and select antibodies targeting unique regions outside the conserved RhoGAP domain

Fixation-dependent epitope accessibility:

• Problem: Different fixation methods can dramatically affect ARHGAP17 epitope accessibility

• Solution: Test multiple fixation protocols (4% PFA, methanol, or glutaraldehyde) to determine optimal conditions for your specific antibody

Subcellular localization misinterpretation:

• Problem: ARHGAP17 localizes to multiple subcellular compartments, including cytosol, plasma membrane, and specific structures like tight junctions and invadopodia

• Solution: Use super-resolution microscopy and co-localization with established markers to precisely define ARHGAP17 distribution

Inconsistent results between applications:

• Problem: An antibody that works well for western blotting may perform poorly in immunofluorescence

• Solution: Validate each antibody independently for each application and consider using application-specific antibodies (e.g., conjugated forms for flow cytometry)

By anticipating these challenges, researchers can design more robust experiments with appropriate controls and validation steps.

How should ARHGAP17 antibody data be interpreted in the context of autoimmune encephalitis research?

Recent research has identified ARHGAP17 as a potential additional target antigen in autoimmune cerebellar ataxia (ACA), requiring specific considerations when interpreting ARHGAP17 antibody data:

• Cross-reactivity analysis: Consider that patient sera positive for ARHGAP26 antibodies (anti-Ca) may show additional reactivity with ARHGAP17 due to sequence homology in the RhoGAP domain

• Significance of signal strength: When evaluating microarray data, note that while ARHGAP26 showed the strongest IgG reaction (rank 1, 55,232 median FU), ARHGAP17 still produced significant signal (rank 31, 9,296.5 median FU)

• Clinical correlation: The degree of additional reactivity/cross-reactivity with ARHGAP17 might explain observed differences between patients regarding disease severity, treatment response, lesion sites, or clinical presentation

• Z-factor analysis: Use Z-factor values to assess reliability of signals (Z-factor of 0.89 for ARHGAP17 with cut-off at 0.4 indicates high confidence)

These findings suggest that autoimmune encephalitis may involve cross-reactivity to multiple structurally related proteins with different expression patterns throughout the CNS, potentially explaining clinical heterogeneity in patients with the same autoantibody-defined disorder .

What quantitative approaches should be used to analyze ARHGAP17's role in invadopodia dynamics?

Rigorous quantitative analysis is essential when investigating ARHGAP17's role in invadopodia regulation:

For invadopodia formation analysis:

• Quantify percentage of cells forming invadopodia under different conditions (e.g., 28.7% in control vs. 79.3% in ARHGAP17 knockdown cells)

• Measure invadopodia cluster size and number per cell

• Perform time-course experiments tracking invadopodia dynamics at multiple timepoints (10, 20, 30, 60 minutes post-stimulation)

For functional assays:

• Quantify matrix degradation area (3-fold increase observed in ARHGAP17 knockout cells)

• Measure 3D invasion using spheroid growth assays or inverse invasion assays

• Calculate invasion depth in 3D matrices

For localization studies:

• Use STORM reconstructions to precisely define ARHGAP17's spatial organization within invadopodia

• Compare intensity distribution patterns of ARHGAP17 with core markers (F-actin, cortactin) and ring markers (paxillin)

• Perform line-scan analysis to quantify the spatial relationship between ARHGAP17 and other invadopodia components

These quantitative approaches provide robust data on how ARHGAP17 regulates invadopodia formation and function in cancer cells.

How can contradictory results with different ARHGAP17 antibodies be reconciled?

When faced with contradictory results using different ARHGAP17 antibodies, consider these reconciliation approaches:

Epitope mapping and antibody characterization:

• Compare epitope regions recognized by different antibodies

• Antibodies targeting different domains may yield different results due to protein conformation or interactions

• For example, antibodies targeting the internal region (amino acids 303-327) have shown reliable performance in multiple applications

Technical variations:

• Test whether discrepancies arise from methodological differences:

  • Fixation methods (PFA vs. methanol)

  • Permeabilization conditions

  • Antibody concentrations

  • Incubation times/temperatures

Validation using genetic tools:

• Validate all antibodies using ARHGAP17 knockout controls

• Perform rescue experiments with re-expressed ARHGAP17 to confirm specificity

• Use multiple shRNA or CRISPR sequences targeting ARHGAP17 to confirm phenotypes

Contextual differences:

• Consider that ARHGAP17 function and localization may vary between cell types

• Cell density and confluence can affect tight junction formation and ARHGAP17 localization

• Activation state of cells (e.g., PDBu treatment) significantly affects ARHGAP17 localization to invadopodia

How might ARHGAP17 antibodies contribute to understanding cross-talk between tight junction integrity and cancer invasion?

ARHGAP17's dual role in maintaining tight junctions and regulating invadopodia suggests a potential mechanistic link between epithelial barrier function and cancer invasion:

• Shared signaling pathways: ARHGAP17 antibodies can help identify common downstream effectors regulated by ARHGAP17 in both tight junctions and invadopodia, particularly focusing on Cdc42 regulation

• Epithelial-mesenchymal transition (EMT): Investigate how ARHGAP17 expression and localization changes during EMT, potentially serving as a molecular switch between epithelial integrity and invasive phenotypes

• Spatial regulation: Use super-resolution microscopy with ARHGAP17 antibodies to analyze how its subcellular distribution changes during the transition from normal epithelium to invasive cancer

• Protein interaction networks: Combine ARHGAP17 antibodies with proximity labeling approaches to map differential interaction partners in epithelial versus invasive contexts

This research direction could provide insights into the molecular mechanisms underlying cancer progression from contained epithelial tumors to invasive malignancies.

What novel approaches could enhance detection of ARHGAP17 autoantibodies in neurological disorders?

Current evidence suggests ARHGAP17 may be an additional target antigen in autoimmune cerebellar ataxia, prompting development of improved detection methods:

• Multiplex assays: Develop assays that simultaneously detect autoantibodies against multiple ARHGAP family members (ARHGAP17, ARHGAP26, ARHGAP10) to capture the full spectrum of cross-reactivity

• Epitope-specific detection: Design assays targeting the shared RhoGAP domain versus unique protein regions to differentiate between specific and cross-reactive antibodies

• Live cell-based assays: Utilize cells expressing ARHGAP17 on their surface to detect conformationally-relevant autoantibodies that might be missed by conventional assays

• Correlation analysis: Implement statistical approaches to analyze the correlation between ARHGAP17-IgG and ARHGAP26-IgG titers, which could help distinguish between cross-reactivity and distinct antibody populations

These advanced approaches may improve diagnosis of autoimmune encephalitis and reveal new subtypes with distinct clinical features and treatment responses.

How could emerging technologies enhance ARHGAP17 antibody applications in research?

Several cutting-edge technologies could transform how ARHGAP17 antibodies are used in research:

• Super-resolution microscopy: Beyond STORM, other super-resolution techniques like PALM, STED, or expansion microscopy could provide novel insights into ARHGAP17's nanoscale organization and dynamics

• Live-cell single-molecule tracking: Combining antibody fragments with quantum dots or other bright fluorophores could enable tracking of endogenous ARHGAP17 dynamics in living cells

• Proximity proteomics: Using antibodies to validate BioID or APEX2-based proximity labeling results could map the complete ARHGAP17 interaction network in specific subcellular locations

• Spatial transcriptomics integration: Correlating ARHGAP17 protein localization with spatial transcriptomics data could reveal local translation regulation and mRNA localization patterns

• Cryo-electron tomography: Using antibodies as fiducial markers in cryo-ET could place ARHGAP17 within the native 3D ultrastructure of tight junctions or invadopodia

These technological advances could provide unprecedented insights into ARHGAP17's functions across diverse cellular contexts and disease states.